Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201703-13 Development of bispecific antibody therapeutics for Parkinson’s disease with improved BBB penetration and target specificity(CNS Diseases, Protein) [2019-03-18]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of bispecific antibody therapeutics for Parkinson’s disease with improved BBB penetration and target specificity.

Unmet Medical Need & Target Patients

1. Unmet Medical Need

- Only symptomatic relief by current therapeutics

- No disease-modifying therapies that halt or lessen disease progression

- No or limited efficacy of current therapeutics for non-motor symptoms

 

2. Target patients

 Patients at early stage of Parkinson’s disease and alpha-synuclein-related diseases

Status

1. Confirmed alpha-synuclein removal, inhibition of cell-to-cell transmission, and reduction of neuroinflammation with treatment of lead antibodies in an animal model for Parkinson’s disease.

2. Selected antibodies that show efficacy of BBB crossing using a mechanism of receptor-mediated transcytosis.

Intellectual Property

Non-disclosure

Competitive Advantages

- Aggregated form of alpha-synuclein is thought to be disease-specific  and has been focused as one of the fundamental culprits in Parkinson’s disease. Various approaches including siRNA and small molecule drugs have been developed with an expect to remove the aggregated form, but these drugs have shown s minimal efficacy or raise a concern about their possibly due to low BBB penetrating activity.

- In case of antibody therapeutics being developed by major global pharmaceuticals, most of them do not distinguish alpha-synuclein monomers and aggregates. Additionally,  these antibodies have very limited access to the brains and target antigens in the brains because they do not have a BBB shuttle that allows them to pass the BBB, presumably leading to low therapeutic efficacy.

- It is expected that ABL’s bispecific antibody possessing BBB penetrating shuttle and target specific binder shows low adverse effect and significant efficacy with improved target reach as first-in-class therapeutics.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code